HTF Market Intelligence released a new research report of 188 pages on title ‘Diabetic Retinopathy – Pipeline Review, H1 2017’ with detailed analysis, forecast and strategies. The study covers key regions and important players such as Kowa Company Ltd, Lupin Ltd, M’s Science Corp etc.
Request a sample report @ https://www.htfmarketreport.com/sample-report/454863-diabetic-retinopathy-pipeline-review
Diabetic Retinopathy – Pipeline Review, H1 2017
The latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Retinopathy – Pipeline Review, H1 2017, provides an overview of the Diabetic Retinopathy (Metabolic Disorders) pipeline landscape.
Diabetic retinopathy is a complication of diabetes that affects the eyes. Diabetic retinopathy symptoms may include spots or dark strings floating in your vision (floaters), blurred vision, fluctuating vision, vision loss and difficulty with color perception. The predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy and tobacco use.
The Pharmaceutical and Healthcare latest pipeline guide Diabetic Retinopathy – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Diabetic Retinopathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Diabetic Retinopathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Retinopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 7, 5, 1, 34, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 6 molecules, respectively.
Diabetic Retinopathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=454863
– The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Retinopathy (Metabolic Disorders).
– The pipeline guide reviews pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Diabetic Retinopathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Diabetic Retinopathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Diabetic Retinopathy (Metabolic Disorders).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Diabetic Retinopathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned in the Report
Aerie Pharmaceuticals Inc
Aerpio Therapeutics Inc
Antisense Therapeutics Ltd
Apollo Endosurgery Inc
BCN Peptides SA
Biomar Microbial Technologies
Coherus BioSciences Inc
Crinetics Pharmaceuticals Inc
Dimerix Bioscience Pty Ltd
Dynamis Therapeutics Inc
Foresee Pharmaceuticals LLC
Icon Bioscience Inc
Islet Sciences Inc
Kodiak Sciences Inc
Kowa Company Ltd
M’s Science Corp
Nemus Bioscience Inc
Ohr Pharmaceutical Inc
Regeneron Pharmaceuticals Inc
Strongbridge Biopharma plc
VESSL Therapeutics Ltd
Make an enquiry before buying this Report @ https://www.htfmarketreport.com/enquiry-before-buy/454863-diabetic-retinopathy-pipeline-review
Table of Contents
Diabetic Retinopathy – Overview 6
Diabetic Retinopathy – Therapeutics Development 7
Diabetic Retinopathy – Therapeutics Assessment 18
Diabetic Retinopathy – Companies Involved in Therapeutics Development 28
Diabetic Retinopathy – Drug Profiles 46
Diabetic Retinopathy – Dormant Projects 165
Diabetic Retinopathy – Discontinued Products 169
Diabetic Retinopathy – Product Development Milestones 170
Appendix 180List of Tables
Number of Products under Development for Diabetic Retinopathy, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/454863-diabetic-retinopathy-pipeline-review
CRAIG FRANCIS (PR & Marketing Manager)
Ph: +1 (206) 317 1218